^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    HPK1 inhibitor

    Related drugs:
    19d
    Mitogen-activated Protein Kinase big Mitogen-activated Kinase-1 Mediates Protection in Liver Ischemia/Reperfusion Injury. (PubMed, Transplantation)
    This study documents the crucial role/underlying mechanism of BMK1 signaling and points to a novel target to minimize hepatocellular dysfunction in IR-stressed liver transplantation.
    Journal
    |
    KLF4 (Kruppel-like factor 4) • LATS1 (Large Tumor Suppressor Kinase 1) • UBR5 (Ubiquitin Protein Ligase E3 Component N-Recognin 5)
    1m
    HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results. (PubMed, Cell Rep Med)
    In clear cell renal cell carcinoma, the investigator-assessed overall response rate with monotherapy treatment is 13.6%, including one complete response and two partial responses, with a clinical benefit rate of 27.3% and a disease control rate of 54.5%. Pharmacodynamic analyses show pharmacodynamic biomarker phospho-SLP76 inhibition and increased activated CD8+ T cells and dendritic cells in the TME, supporting continued development (clinical registration number NCT05128487).
    P1/2 data • Journal • PD(L)-1 Biomarker
    |
    CD8 (cluster of differentiation 8) • LCP2 (Lymphocyte cytosolic protein 2)
    |
    Keytruda (pembrolizumab)
    3ms
    HERKULES-3: A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies (clinicaltrials.gov)
    P1/2, N=101, Completed, Erasca, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600
    |
    Erbitux (cetuximab) • Ibrance (palbociclib) • Braftovi (encorafenib) • ERAS-007
    3ms
    DCC-3084-01-001: Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway (clinicaltrials.gov)
    P1, N=29, Terminated, Deciphera Pharmaceuticals, LLC | Phase classification: P1/2 --> P1 | N=140 --> 29 | Trial completion date: Aug 2027 --> Feb 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2026 --> Feb 2026; Trial terminated due to a business decision, not based on any safety concerns.
    Phase classification • Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • NF1 (Neurofibromin 1) • RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase)
    |
    BRAF mutation
    |
    DCC-3084
    5ms
    A Phase I First-in-Human Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of SWA1211 Tablets in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=60, Recruiting, Beijing StoneWise Technology Co., Ltd
    New P1 trial • First-in-human
    5ms
    Hematopoietic progenitor kinase 1 inhibitor BGB-15025 induces apoptosis in acute myeloid leukemia cells through the cell cycle pathway and mitogen-activated protein kinase/extracellular signal-regulated kinase pathway signaling axis. (PubMed, Anticancer Drugs)
    In-vivo studies demonstrated a reduced leukemia burden in xenograft models. This study is the first to elucidate that BGB-15025 triggers AML apoptosis through cell cycle blockade and MAPK pathway inhibition, thereby proposing a novel precision therapeutic strategy with significant clinical translational value.
    Journal
    |
    CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    |
    BGB-15025
    5ms
    BGB-A317-15025-101: BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=157, Active, not recruiting, BeiGene | Trial completion date: Oct 2026 --> May 2026
    Trial completion date
    |
    Tevimbra (tislelizumab-jsgr) • BGB-15025
    6ms
    A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=39, Active, not recruiting, Zhuhai Yufan Biotechnologies Co., Ltd | Trial completion date: Oct 2024 --> Jun 2026 | Completed --> Active, not recruiting
    Enrollment closed • Trial completion date • First-in-human
    7ms
    A Phase 1 Study of BB3008 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=42, Active, not recruiting, Broadenbio Ltd., Co. | Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2025 --> May 2025
    Enrollment closed • Trial primary completion date
    8ms
    Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG) (clinicaltrials.gov)
    P2, N=79, Not yet recruiting, Nationwide Children's Hospital
    New P2 trial
    |
    BRAF (B-raf proto-oncogene)
    |
    Ojemda (tovorafenib)
    8ms
    DCC-3084-01-001: Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway (clinicaltrials.gov)
    P1/2, N=140, Active, not recruiting, Deciphera Pharmaceuticals, LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    DCC-3084